

Supplementary Table 6. Effectiveness parameters in empagliflozin users: week 12

| Variable | No. of patients | Baseline visit | Week 12 visit | Difference ^a | P value ^b |
|----------------------------------|-----------------|----------------|---------------|-------------------------|----------------------|
| HbA1c, % | 2,211 | 8.00±1.40 | 7.32±1.07 | -0.68±1.33 | <0.0001 ^a |
| Week 12 HbA1c <7.0 | | | 944 (42.70) | | |
| More than 0.5% reduction | | | 1,092 (49.39) | | |
| FPG, mg/dL | 1,961 | 164.16±54.03 | 139.12±42.57 | -25.04±59.07 | <0.0001 ^a |
| Weight, kg | 1,955 | 74.87±14.04 | 73.50±13.77 | -1.37±2.76 | <0.0001 ^a |
| SBP, mmHg | 2,223 | 129.63±15.02 | 126.23±14.19 | -3.40±14.59 | <0.0001 ^a |
| DBP, mmHg | 2,222 | 77.76±10.61 | 76.51±10.57 | -1.25±10.46 | <0.0001 ^a |
| eGFR, mL/min/1.73 m ² | 367 | 93.32±21.15 | 91.98±21.44 | -1.34±14.77 | 0.0456 ^a |
| Serum creatinine, mg/dL | 367 | 0.82±0.17 | 0.82±0.19 | 0.01±0.11 | 0.3682 |
| Urine ACR, mg/g | 20 | 29.32±26.73 | 27.88±25.93 | -1.44±13.99 | 0.6505 |

Values are presented as mean ± standard deviation or number (%).

HbA1c, glycosylated hemoglobin; FPG, fasting plasma glucose; SBP, systolic blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; ACR, albumin/creatinine ratio.

^aDifference: (last visit)-(baseline visit), ^bWilcoxon signed-rank test.